High prevelance of human parvovirus infection in patients with malignant tumors

Li,Yasha; Dong,Yanming; Jiang,Jun; Yang,Yongbo; Liu,Kaiyu; Li,Yi

doi:10.3892/ol.2012.548

High prevelance of human parvovirus infection in patients with malignant tumors

Authors:
- Yasha Li
- Yanming Dong
- Jun Jiang
- Yongbo Yang
- Kaiyu Liu
- Yi Li
View Affiliations

Affiliations: College of Life Science, Central China Normal University, Wuhan 430072, P.R. China
Published online on: January 3, 2012 https://doi.org/10.3892/ol.2012.548
Pages: 635-640

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is well known that the immunity of patients with malignant tumors decreases significantly. An increased parvovirus B19 (B19) infection rate has been observed in immunocompromised hosts. However, only a small amount of literature regarding the risk of human parvovirus infection in patients with malignant tumors is available. To evaluate the correlation of human parvovirus infection with malignant tumors, 288 serum samples from patients with malignant tumors were screened for B19 DNA by nested-PCR. The serum samples, 156 of which were from known clinicopathological cancer patients, were subjected to analysis of the seropositive rate of human bocavirus (HBoV), hepatitis B virus (HBV) and transfusion transmitted virus (TTV) by PCR. A total of 800 normal population sera and 941 aspirate samples from children with respiratory tract infections were used as controls for the detection of B19 and HBoV, respectively. Pairwise comparison between cancerous serum and control samples, and the correlation between parvovirus infection and clinicopathological variables, including gender and cancer type, were evaluated using the χ2 test, Fisher's exact test or the t-test. P<0.05 was considered to indicate a statistically significant difference. The overall prevalence of B19 DNA in cancer patients was 50.69% (146/288), which was significantly higher than that of the healthy controls with 4.5% (36/800) (χ2 test, P<0.0001). Similar results were obtained for HBoV with a 39.74% (62/156) prevalence in cancer patients. However, the infection prevalence of HBV and TTV in the cancer patients was 5.13 (8/156) and 6.41% (10/156), respectively (P<0.0001), which was much less than that of B19 and HBoV. These results revealed that a high risk of B19 and HBoV infection occurred in cancer patients, and a potential correlation exists between parvovirus infection and occurrence of malignant tumors.

View Figures

View References

1	Ozawa K and Young NS: Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow culture. J Virol. 61:2627–2630. 1987.PubMed/NCBI
2	Bultmann BD, Klingel K, Sotlar K, et al: Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch. 442:8–17. 2003.PubMed/NCBI
3	Anderson MJ, Higgins PG, Davis LR, et al: Experimental parvoviral infection in humans. J Infect Dis. 152:257–265. 1985. View Article : Google Scholar : PubMed/NCBI
4	Kelleher JF, Luban NL, Mortimer PP and Kamimura T: Human serum parvovirus: a specific cause of aplastic crisis in children with hereditary spherocytosis. J Pediatr. 102:720–722. 1983. View Article : Google Scholar : PubMed/NCBI
5	Pattison JR, Jones SE, Hodgson J, et al: Parvovirus infections and hypoplastic crisis in sickle-cell anemia. Lancet. 317:664–665. 1981. View Article : Google Scholar : PubMed/NCBI
6	Reid DM, Reid TM, Brown T, et al: Human parvovirus associated arthritis: a clinical and laboratory description. Lancet. 325:422–425. 1985. View Article : Google Scholar
7	Kinney JS, Anderson LJ, Farrar J, et al: Risk of adverse outcomes of pregnancy after human parvovirus B infection. J Infect Dis. 7:663–667. 1988. View Article : Google Scholar : PubMed/NCBI
8	Torok TJ: Unusual clinical manifestations reported in patients with parvovirus B19 infection. Monogr. 20:61–92. 1997.
9	Ahsan N, Holman MJ, Gocke CD, et al: Pure red cell aplasia due to parvovirus B19 infection in solid organ transplantation. Clin Transpl. 11:265–270. 1997.PubMed/NCBI
10	Chernak E, Dubin G, Henry D, et al: Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis. 20:170–173. 1995. View Article : Google Scholar : PubMed/NCBI
11	Kurtzman GJ, Ozawa K, Cohen B, et al: Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med. 317:287–294. 1987. View Article : Google Scholar : PubMed/NCBI
12	Allander T, Tammi MT, Eriksson M, et al: Cloning of a human parvovirus by molecular sereening of respiratory tract samples. Proc Natl Acad Sci USA. 102:12891–12898. 2005. View Article : Google Scholar : PubMed/NCBI
13	Allander T: Human bocavirus. J Clin Virol. 41:29–33. 2008. View Article : Google Scholar
14	Lindner J, Karalar L, Schimanski S, et al: Clinical and epidemiological aspects of human bocavirus infection. J Clin Virol. 43:391–395. 2008. View Article : Google Scholar : PubMed/NCBI
15	Tozer SJ, Lambert SB, Whiley DM, et al: Detection of human bocavirus in respiratory, fecal, and blood samples by real-time PCR. J Med Virol. 81:488–493. 2009. View Article : Google Scholar : PubMed/NCBI
16	Fry AM, Lu X, Chittaganpitch M, et al: Human bocavirus: a novel parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand. J Infect Dis. 195:1038–1045. 2007. View Article : Google Scholar : PubMed/NCBI
17	Allander T, Jartti T, Gupta S, et al: Human bocavirus and acute wheezing in children. Clin Infect Dis. 44:904–910. 2007. View Article : Google Scholar : PubMed/NCBI
18	Neske F, Blessing K, Tollmann F, et al: Real-time PCR for diagnosis of human bocavirus infections and phylogenetic analysis. J Clin Microbiol. 45:2116–2122. 2007. View Article : Google Scholar : PubMed/NCBI
19	Vicente D, Cilla G, Montes M, et al: Human bocavirus, a respiratory and enteric virus. Emerg Infect Dis. 13:636–637. 2007. View Article : Google Scholar : PubMed/NCBI
20	Pozo F, García-García ML, Calvo C, et al: High incidence of human bocavirus infection in children in Spain. J Clin Virol. 40:224–228. 2007. View Article : Google Scholar : PubMed/NCBI
21	Kesebir D, Vazquez M, Weibel C, et al: Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J Infect Dis. 194:1276–1282. 2006. View Article : Google Scholar
22	Maggi F, Andreoli E, Pifferi M, et al: Human bocavirus in Italian patients with respiratory diseases. J Clin Virol. 38:321–325. 2007. View Article : Google Scholar : PubMed/NCBI
23	García-García ML, Calvo C, Pozo F, et al: Human bocavirus detection in nasopharyngeal aspirates of children without clinical symptoms of respiratory infection. Pediatr Infect Dis J. 27:358–360. 2008.PubMed/NCBI
24	Wang K, Wang W, Yan H, et al: Correlation between bocavirus infection and humoral response, and co-infection with other respiratory viruses in children with acute respiratory infection. J Clin Virol. 47:148–155. 2010. View Article : Google Scholar : PubMed/NCBI
25	Young NS: Parvoviruses. Fields Virology. Knipe DM and Howley PM: 3rd edition. Lippincott, Williams and Wilkins; Philadelphia, USA: pp. 2199–2220. 1996
26	Kurtzman GJ, Cohen BJ, Field AM, et al: Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest. 84:1114–1123. 1989. View Article : Google Scholar : PubMed/NCBI
27	Sung HK, Lin LI, Chang CJ, et al: Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy. J Clin Microbiol. 40:3909–3912. 2002. View Article : Google Scholar : PubMed/NCBI